In Vivo Incorporation of Unnatural Amino Acids

$473,750R01FY2015GMNIH

Scripps Research Institute, The, La Jolla CA

Investigators

Linked publications, trials & patents

Paper 33468658 Paper 33069069 Paper 31181898 Paper 30433771 Paper 29360343 Paper 29345901 Paper 28857557 Paper 28809560 Paper 28604693 Paper 28593724 Paper 28371162 Paper 27762133 Paper 27704775 Paper 27213685 Paper 27145250 Paper 26976568 Paper 26759369 Paper 26759368 Paper 26434555 Paper 25919418 Paper 25056598 Paper 25044800 Paper 24574221 Paper 24443971 Paper 24254636 Paper 24127589 Paper 23941200 Paper 23924161 Paper 23924037 Paper 23818609 Paper 23795814 Paper 23794517 Paper 23746848 Paper 23664497 Paper 23440204 Paper 23210862 Paper 22988081 Paper 22689270 Paper 22642368 Paper 22345566 Paper 21945294 Paper 21890355 Paper 21823631 Paper 21768354 Paper 21690365 Paper 21681882 Patent 9624485 Patent 9249408 Patent 9150849 Patent 9109022 Patent 8673591 Patent 8647840 Patent 8394605 Patent 8361770 Patent 8318172 Patent 8217145 Patent 8183012 Patent 8173392 Patent 8173364 Patent 8114652 Patent 8114648 Patent 8114629 Patent 8114628 Patent 8114627 Patent 8071344 Patent 8030074 Patent 8030028 Patent 8012739 Patent 7915025 Patent 7888063 Patent 7834159 Patent 7825226 Patent 7824893 Patent 7794978 Patent 7790847 Patent 7718410 Patent 7713721 Patent 7642085 Patent 7638300 Patent 7638297 Patent 7625717 Patent 7618775 Patent 7608423 Patent 7575895 Patent 7560535 Patent 7527943 Patent 7524647 Patent 7432092 Patent 7399619 Patent 7368275 Patent 7354761 Patent 7262040 Patent 7238510 Patent 7217809 Patent 7199222 Patent 7183082 Patent 7129333 Patent 7083970 Patent 7045337 Patent 6927042

Abstract

DESCRIPTION (provided by applicant): This proposal is aimed at further developing and applying a general method that allows one to systematically add amino acids with novel physical, chemical and biological properties to the genetic codes of both prokaryotic and eukaryotic organisms. This methodology involves the generation of orthogonal tRNA/aminoacyl-tRNA synthetase (aaRS) pairs that uniquely recognize a noncoding codon and do not cross react with any of the endogenous tRNAs and aminoacyl-tRNA synthetases in the host organism. The amino acid specificity of the aminoacyl-tRNA synthetase is then modified such that it aminoacylates its cognate tRNA with only the desired unnatural amino acid and no endogenous amino acid. Using this method, a large number of structurally diverse unnatural amino acids have been incorporated efficiently and with high fidelity into proteins in response to nonsense and frameshift codons. We now propose to extend these studies in several directions. The first is focused on developing robust, user-friendly methods to genetically encode a large number of these unnatural amino acids in mammalian cells and Streptomyces. If successful this effort will significantly expand the scope and impact of this technology. The second effort focuses on the synthesis and in vitro and in vivo characterization of chemically defined antibody conjugates for the treatment of cardiovascular disease and acute myeloid leukemia. These latter efforts should not only pave the way for new or significantly improved therapeutics for major unmet medical needs, they should also provide a generalizable, straightforward approach to create similar classes of antibody conjugates for metabolic, cardiovascular and inflammatory diseases.

View original record on NIH RePORTER →